Upcycling umbilical cords: bridging regenerative medicine with neonatology

Area of Science:

• Regenerative Medicine
• Neonatal Health
• Stem Cell Therapy

Background:

• Preterm birth impacts 10% of global deliveries, often leading to significant infant morbidities and lifelong conditions.
• Current treatments for preterm infant morbidities are largely palliative, highlighting the need for innovative therapeutic approaches.
• Regenerative medicine, particularly stem cell therapies, presents potential curative options.

Purpose of the Study:

• To review the therapeutic potential and clinical applications of human umbilical cord mesenchymal stem cells (MSCs) and cord blood (UCB) cells for neonates.
• To summarize current research on the use of umbilical cord-derived cells in treating preterm infants.
• To bridge the gap between promising preclinical findings and clinical investigation in neonatal care.

Main Methods:

• Review of preclinical studies and existing literature on umbilical cord MSCs and UCB cells.
• Analysis of the properties of umbilical cord-derived stem cells, including ease of acquisition and low immunogenicity.
• Focus on the transition of research from adult applications to neonatal therapeutic strategies.

Main Results:

• Human umbilical cord MSCs and UCB cells show promise for treating adult diseases.
• Umbilical cord-derived cells are easily obtained, have low immunogenicity, and allow for autologous therapy.
• Preclinical data supports the potential of cell-based therapies for preterm infants, driving current research efforts.

Conclusions:

• Umbilical cord stem cells represent a significant advancement in regenerative medicine for neonatal care.
• There is a critical need to further investigate the efficacy and safety of these cells in treating preterm infants.
• Cell-based therapies hold promise for developing curative strategies for conditions affecting preterm infants, moving beyond palliative care.